Ellomay Capital (NYSEAMERICAN:ELLO – Get Free Report) released its quarterly earnings data on Sunday. The utilities provider reported ($0.34) EPS for the quarter, reports. Ellomay Capital had a net margin of 3.24% and a return on equity of 3.01%. The business had revenue of $8.91 million during the quarter.
Ellomay Capital Trading Down 0.4 %
ELLO opened at $12.08 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 3.16. Ellomay Capital has a 1 year low of $10.00 and a 1 year high of $20.26. The firm has a market capitalization of $155.23 million, a P/E ratio of 38.60 and a beta of 1.25.
Hedge Funds Weigh In On Ellomay Capital
A hedge fund recently raised its stake in Ellomay Capital stock. Clal Insurance Enterprises Holdings Ltd grew its holdings in Ellomay Capital Ltd. (NYSEAMERICAN:ELLO – Free Report) by 54.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,512,554 shares of the utilities provider’s stock after buying an additional 534,554 shares during the period. Clal Insurance Enterprises Holdings Ltd owned 11.77% of Ellomay Capital worth $22,580,000 as of its most recent filing with the Securities & Exchange Commission. 27.54% of the stock is owned by hedge funds and other institutional investors.
Ellomay Capital Company Profile
Ellomay Capital Ltd., together with its subsidiaries, engages in the initiation, development, construction, and production of renewable and clean energy projects in Spain, the United States, Italy, the Netherlands, and Israel. The company owns photovoltaic (PV) plants comprising five PV plants in Spain with an aggregate installed capacity of approximately 35.9 megawatts (MW); and one PV plant with an installed capacity of 300 MW in the municipality of Talaván, Spain.
Read More
- Five stocks we like better than Ellomay Capital
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Does BJ’s Wholesale Club Stock Have More Room to Grow?
- What is a Special Dividend?
- Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
- What to Know About Investing in Penny Stocks
- RXO Shares Surge Following New Acquisition Deal
Receive News & Ratings for Ellomay Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ellomay Capital and related companies with MarketBeat.com's FREE daily email newsletter.